Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 16/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430905 | 0.84 | GRIK1 (1.00) | GRIK1MEN1KMT2AGRIK2 | |
| Cloflucarban SCHEMBL119821 | 0.83 | KDR (0.88) | KDRMEN1KMT2ATRPV1TMPRSS4 | |
| Cloflucarban SCHEMBL27537485 | 0.83 | KDR (0.88) | KDRMEN1KMT2ATRPV1TMPRSS4 | |
| SCHEMBL29364392 | 0.83 | KDR (1.00) | KDRTRPV1 | |
| SCHEMBL118026 | 0.83 | KDR (1.00) | KDRTRPV1 | |
| SCHEMBL1462337 | 0.81 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL1463260 | 0.81 | GRIK1 (0.81) | GRIK1MEN1KMT2ATMPRSS4 | |
| SCHEMBL3962623 | 0.81 | GRIK1 (1.00) | GRIK1MEN1KMT2AGRIK2 | |
| SCHEMBL5950341 | 0.81 | KDR (0.65) | GRIK1KDRMEN1KMT2ATRPV1 | |
| SCHEMBL5950453 | 0.81 | KDR (0.68) | KDRTRPV1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | GRIK1 655/4885KDR 4778/4885MEN1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.